Nigel,
I'm putting RNAI in the WatchList, and will short it tomorrow, unless someone stops me. They'll need to finance long before they get anything in the clinic, VC control some 86% of the stock at much cheaper prices. Fresh grants of warrants and options, forgiven loans, wow. I cannot find the terms of the warrants, nor any lock-up agreement on all those shares the VC now hold. If anyone can find that information, please post it here. this has come way to far too fast on hype, IMO. On top of the overhang and financial risks, there's the IP issue. RNAi IP is still quite murky. Delivery of siRNA is currently problematic in mammalian cells. Today it seemed to be riding on the general hype of the promise of anti-angiogenesis & ASCO, though I know of no presentations by the company there . . .
Cheers, Tuck |
